Phase 2 Crohn's Disease and Colitis Trial, Recruiting NCT05574387 Sponsor: Tanta University Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 2 Crohn's Disease and Colitis Trial, Recruiting

NCT05574387
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older, of any gender
  • People who have tested negative for pregnancy and are using effective contraception
  • People who have been diagnosed with mild or moderate ulcerative colitis (a type of inflammatory bowel condition), confirmed by a camera examination of the bowel (endoscopy)

Who may not be able to join:

  • People who are currently breastfeeding
  • People who have significant problems with their liver or kidney function
  • People who have diabetes
  • People who have colorectal cancer (cancer of the large bowel or rectum)
  • People who have severe ulcerative colitis
  • People who are currently using steroid medications, either taken by mouth/injection or applied directly to the rectum

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 0201025538337

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Tanta University
Registry
ClinicalTrials.gov
Start date
20 January 2023
Est. completion
1 December 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Improvement in HRQL through changes in inflammatory bowel disease questionnaire (IBDQ) score and change in mayo scores

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov